Provided by Tiger Trade Technology Pte. Ltd.

Aldeyra Therapeutics

4.77
-0.0250-0.52%
Volume:664.11K
Turnover:3.16M
Market Cap:286.68M
PE:-6.61
High:4.81
Open:4.77
Low:4.68
Close:4.79
52wk High:7.20
52wk Low:1.14
Shares:60.16M
Float Shares:48.48M
Volume Ratio:0.54
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7210
EPS(LYR):-0.9389
ROE:-64.31%
ROA:-28.94%
PB:5.82
PE(LYR):-5.07

Loading ...

Aldeyra Therapeutics Showcases Broad Immunology Pipeline Targeting Immune-Mediated Diseases in New R&D Presentation

Reuters
·
Nov 13

BRIEF-Aldeyra Therapeutics Announces Expansion of RASP Platform

Reuters
·
Nov 13

Aldeyra Therapeutics Reports Positive Preclinical Results for ADX-248 in Neurological Disease Models

Reuters
·
Nov 13

Aldeyra Therapeutics Announces Expansion of Rasp Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

THOMSON REUTERS
·
Nov 13

Aldeyra Therapeutics to Join Jefferies Global Healthcare Conference in London

Reuters
·
Nov 11

Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG

Dow Jones
·
Nov 10

Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Nov 04

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.
·
Oct 29

Aldeyra ADX-629 achieves statistically significant improvement in liver function

TIPRANKS
·
Oct 28

Aldeyra Therapeutics Reports Positive Phase 2 Results for ADX-629 in Alcohol-Associated Hepatitis

Reuters
·
Oct 28

Aldeyra Therapeutics Inc - Adx-629 Shows Significant Improvement in Liver Function

THOMSON REUTERS
·
Oct 28

Aldeyra Therapeutics Announces Positive Results From Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses Rasp Product Candidate Pipeline on Next-Generation Molecules

THOMSON REUTERS
·
Oct 28

Aldeyra Therapeutics Inc - Cash Runway Extended Into Second Half of 2027

THOMSON REUTERS
·
Oct 28

Aldeyra Therapeutics Advances with Promising Hepatitis Treatment Trial

TIPRANKS
·
Oct 28

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Benzinga_recent_news
·
Oct 10

Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra Therapeutics

TIPRANKS
·
Oct 09

Aldeyra price target raised to $7 from $6 at Jefferies

TIPRANKS
·
Oct 09

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.
·
Sep 29

Alkermes plc Appoints Joshua Reed as New Chief Financial Officer

Reuters
·
Sep 12

Aldeyra Therapeutics Receives Orphan Designation from European Medicines Agency for ADX-2191 to Treat Rare Vitreoretinal Lymphoma

Reuters
·
Aug 28